PSSD and PGAD: a systematic review. 2023

[anacleta]

Selective Serotonin Reuptake Inhibitors, Post-Treatment Sexual Dysfunction and Persistent Genital Arousal Disorder: a systematic review.

Pharmacoepidemiol Drug Saf. 2023 Jun 9. doi: 10.1002/pds.5653.

Livio Tarchi 1, Giuseppe Pierpaolo Merola 1, Ottone Baccaredda-Boy 1, Francesca Arganini 1, Emanuele Cassioli 1, Eleonora Rossi 1, Mario Maggi 2 3, David S Baldwin 4 5 6, Valdo Ricca 1, Giovanni Castellini 1

Affiliations

1. Psychiatry Unit, Department of Health Science, University of Florence, Largo Brambilla 3, Florence, Italy.
2. Endocrinology Unit, Department of Excellence Experimental and Clinical Biomedical Sciences "Mario Serio", University of Florence, Viale Pieraccini 6, Florence, Italy.
3. I.N.B.B. (Istituto Nazionale Biostrutture e Biosistemi), Viale delle Medaglie d'Oro 305, 00136, Rome, Italy.
4. Clinical and Experimental Sciences, Faculty of Medicine, University of Southampton, Southampton, United Kingdom.
5. Southern Health NHS Foundation Trust, Southampton, United Kingdom.
6. University Department of Psychiatry and Mental Health, University of Cape Town, Cape Town, South Africa.[/list]

PMID: 37294623 DOI: 10.1002/pds.5653

Abstract

Adverse effects of selective serotonin reuptake inhibitors (SSRIs) on sexual function have been an important area of research for many years. However, the duration of SSRI-associated sexual adverse effects, and their possible persistence after treatment discontinuation, is still uncertain. The aims of the current systematic review were firstly to identify existing evidence of sexual dysfunction following SSRI discontinuation, and to provide an account of reported symptoms and proposed treatment options; and econdly, to establish whether current literature allows accurate estimates of the prevalence of such sexual dysfunction. Therefore, a systematic review was conducted on PubMed, Embase and Google Scholar ; papers with clinical data regarding patients with persistent sexual dysfunction after SSRI treatment suspension were included. Overall, two retrospective interventional studies, six observational studies and 11 case reports were judged eligible for inclusion. It was not possible to determine reliable estimates of prevalence. Similarly, a cause-effect relationship between SSRI exposure and persistent sexual impairment could not be ascertained. Nonetheless, the potential for continued sexual disturbances despite discontinuation could not be entirely ruled out. There is a need to investigate a possible dose-response relationship between SSRI exposure and persistent sexual adverse effects. Treatment options for persistent dysfunctions remain limited, but novel therapeutic approaches may be required in order to address an otherwise neglected need for sexual well-being.

https://onlinelibrary.wiley.com/doi/10.1002/pds.5653

[DrugsAreBad]

the potential for continued sexual disturbances despite discontinuation could not be entirely ruled out

Wow, progress.

Seriously these side effects can be found as far back as Usenet in the early 90s. I don't know why they even bother writing this.

Next up: Water may be wet.